Elevated Anxiety, Hypoactivity, Memory Deficits, Decreases of Brain Serotonin and 5-HT-1A Receptors Expression in Rats Treated with Omeprazole
Overview
Authors
Affiliations
Omeprazole (OM) is one of the most prescribed drugs worldwide for the treatment of hyperacidity and gastric reflux. However, concerns regarding its safety have emerged recently, and the drug is reported to enhance the risk for anxiety and cognitive deficits, particularly in elderly patients. The present study investigated these adverse effects, if any, in adult male rats. Associated changes in brain serotonin (5-hydroxytryptamine; 5-HT) and dopamine metabolism and the expression of 5-HT-1A receptors in the raphe and hippocampus were also determined. The drug was injected . in doses of 10 and 20 mg/kg for 15 days. Both doses of OM decreased motor activity in an open field and impaired learning and memory in the Morris water maze test. Anxiety monitored in an elevated plus maze test was enhanced in rats treated with 20 mg/kg OM only. The levels of 5-HT and its metabolite 5-hydroxyindoleacetic acid and of homovanillic acid, a metabolite of dopamine, determined by HPLC-EC, were decreased in the brain of OM treated rats. The expression of 5-HT-1A receptor, determined by qRT-PCR, was reduced markedly in the hippocampus and moderately in the raphe. Our results provide evidence that OM use can reduce raphe hippocampal serotonin neurotransmission to lead to anxiety/depression and cognitive impairment. There is a need for increased awareness and prescription guidelines for therapeutic use of OM and possibly also other proton pump inhibitors.
Gallic acid alleviates omeprazole-induced depressive behavior and memory impairment.
Samad N, Manzoor N, Irfan A, Khalid A, Ejaz U, Abbas B Naunyn Schmiedebergs Arch Pharmacol. 2025; .
PMID: 39976720 DOI: 10.1007/s00210-025-03812-w.
Neuroprotective effect of niacin in a rat model of obesity induced by high-fat-rich diet.
Manzoor N, Samad N, Bhatti S, Irfan A, Ahmad S, Shazly G Naunyn Schmiedebergs Arch Pharmacol. 2024; .
PMID: 39680102 DOI: 10.1007/s00210-024-03687-3.
Andriolo I, Longo B, de Melo D, de Souza M, Prediger R, da Silva L CNS Neurol Disord Drug Targets. 2024; 23(11):1371-1391.
PMID: 38500273 DOI: 10.2174/0118715273289138240306050532.
Coelho D, Costa Junior D, da Silva D, Alves A, Chaves R, Reboucas M Naunyn Schmiedebergs Arch Pharmacol. 2024; 397(8):6165-6175.
PMID: 38433146 DOI: 10.1007/s00210-024-03023-9.
Murthy J, Hughes S, Travis C, Chalia A, Khan S, Ang-Rabanes M Cureus. 2024; 15(12):e51067.
PMID: 38269224 PMC: 10807343. DOI: 10.7759/cureus.51067.